These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8160638)

  • 1. Breast cancer marker Ca549. A multicenter study.
    Chan DW; Beveridge RA; Bhargava A; Wilcox PM; Kennedy MJ; Schwartz MK
    Am J Clin Pathol; 1994 Apr; 101(4):465-70. PubMed ID: 8160638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the circulating glycoprotein CA549 in mammary cancer and other malignancies.
    Clocchiatti L; De Biasi F; Cartei G; Sibau A; Vigevani E; Signor M; Giovannoni M; Ceschia V; Di Chiara F; Grandis S
    Tumori; 1991 Oct; 77(5):395-8. PubMed ID: 1781036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.
    Gion M; Plebani M; Mione R; Penzo C; Meo S; Burlina A
    Br J Cancer; 1994 Apr; 69(4):721-5. PubMed ID: 8142260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA549 and TPS patterns in the diagnosis and staging of patients with breast carcinoma.
    Vibert HG; Houston AS; Wilkins GP; Kemp PM; Macleod MA
    Int J Biol Markers; 1996; 11(4):198-202. PubMed ID: 9017442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1 serum assays in breast cancer: tumor specificities and reference levels.
    Bjerner J; Norum LF; Nilsson O; Nustad K
    Tumour Biol; 2002; 23(6):315-23. PubMed ID: 12677089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and cytosolic levels of CA549 in breast cancer patients.
    Correale M; Abbate I; Dragone CD; Tedone T; Gargano G; Catino A; Paradiso A; Addabbo L; Musci MD; De Lena M
    Clin Exp Obstet Gynecol; 1993; 20(4):264-7. PubMed ID: 8281711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
    Bray KR; Koda JE; Gaur PK
    Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
    Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
    Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Basic study of CA549, a new tumor marker for breast cancer, and evaluation of its clinical usefulness].
    Yamaguchi A; Ushigome M; Imai T; Otake H; Igarashi H; Hatori N; Tomiyoshi K; Inoue T; Endo K
    Kaku Igaku; 1993 Mar; 30(3):317-22. PubMed ID: 8479100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucin-like carcinoma associated antigen (MCA) at presentation with breast cancer.
    Horgan PG; Byrne J; O'Donoghue J; Mooney E; Grimes H; Given HF
    Ir J Med Sci; 1997; 166(4):215-6. PubMed ID: 9394068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA 549: the theorem of Bayes for obtaining cut-off values.
    Blasco R; Rodriguez Cortasa MJ; Barbero EM; Colmenarejo A; Munoz Calvo R
    Int J Biol Markers; 1992; 7(4):270. PubMed ID: 1491188
    [No Abstract]   [Full Text] [Related]  

  • 12. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System.
    Molina R; Gion M; Gressner A; Troalen F; Auge JM; Holdenrieder S; Zancan M; Wycislo M; Stieber P
    Clin Chem Lab Med; 2008; 46(5):612-22. PubMed ID: 18598203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
    Horobin JM; Browning MC; McFarlane NP; Smith G; Preece PE; Wood RA; Cuschieri A
    J R Coll Surg Edinb; 1991 Aug; 36(4):219-21. PubMed ID: 1941734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating CA 549 and other associated antigens in breast cancer patients.
    Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
    Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevation of multiple serum markers in patients with stage I ovarian cancer.
    Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
    J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OVX1 as a marker for early stage endometrial carcinoma.
    Xu FJ; Yu YH; Daly L; Anselmino L; Hass GM; Berchuck A; Rodriguez GC; Soper JT; Clarke-Pearson DL; Hollis D
    Cancer; 1994 Apr; 73(7):1855-8. PubMed ID: 8137210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.
    Chan DW; Beveridge RA; Muss H; Fritsche HA; Hortobagyi G; Theriault R; Kiang D; Kennedy BJ; Evelegh M
    J Clin Oncol; 1997 Jun; 15(6):2322-8. PubMed ID: 9196146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical and clinical evaluation of a new tumor marker in breast cancer: CA 27.29.
    Correale M; Abbate I; Gargano G; Catino A; Dragone CD; Musci MD; Serio G; Paradiso A; De Lena M
    Int J Biol Markers; 1992; 7(1):43-6. PubMed ID: 1583347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.